X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MYMD-1 (isomyosamine), a next generation, oral selective inhibitor of tumor necrosis factor-alpha, a driver of chronic inflammation, being studied for rheumatoid arthritis.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Supera-CBD™ is a synthetic, non-toxic cannabidiol (CBD) analog that is an 8000-times more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures.
Lead Product(s): Cannabidiol Analog
Therapeutic Area: Neurology Product Name: Supera-CBD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
MYMD-1, a next generation, oral selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated as therapy for delaying aging.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated for rheumatoid arthritis.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The financing will support the continued development of MYMD-1 for sarcopenia, an aging indication. MYMD-1® regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
MYMD-1 (isomyosamine) is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based autoimmune diseases are treated.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
MYMD-1 (isomyosamine) with its ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
